Company Profile (AI Text)
Name: Biostate AI
Canonical URL: https://wefunder.com/biostate.ai
Updated at: 2026-06-07T05:03:14Z

Tagline: General-purpose biomedical AI to help 90% of people live to 90

Key claims:
- Total raised on Wefunder: 124000 | citation: https://wefunder.com/biostate.ai#claim-total-raised
- Total investors: 398 | citation: https://wefunder.com/biostate.ai#claim-total-investors

Verified facts:
- Total raised on Wefunder: 124000 | observed_at: 2026-06-07T05:03:14Z | expires_at: 2026-06-08T05:03:14Z
- Total investors: 398 | observed_at: 2026-06-07T05:03:14Z | expires_at: 2026-06-08T05:03:14Z

Computed metrics:
- total_amount_raised: 124000
- total_investors: 398
- team_size: 5
- featured_investor_count: 10
- faq_count: 5
- recent_post_count: 0

Quick facts:
- $20M raised from leading VCs including Accel, Matter Venture Partners, InfoEdge Ventures, Vision Plus, and Caltech Fund. | citation: https://wefunder.com/biostate.ai#claim-fact-1
- Repeat Founder: previously built $100M+ funded genomic platform with $20M+ revenue (2022). | citation: https://wefunder.com/biostate.ai#claim-fact-2
- 30+ clinical collaborations with top hospitals including Harvard Med School, MD Anderson, Cornell… Accessing 100,000+ patient samples worldwide. | citation: https://wefunder.com/biostate.ai#claim-fact-3
- Active clinical research programs in Leukemia, Melanoma, Lung cancer, Diabetes, Lupus, Multiple Sclerosis, and Coronary Artery Disease | citation: https://wefunder.com/biostate.ai#claim-fact-4
- 15+ Patented technology to reduce RNA & DNA testing cost by 80%+ | citation: https://wefunder.com/biostate.ai#claim-fact-5
- Our AI scientist platform (K-Dense) outperforms ChatGPT-5, Claude, Gemini by 60%+. | citation: https://wefunder.com/biostate.ai#claim-fact-6
- Revolutionizing Precision medicine and Multi-omics, $100B+ markets. | citation: https://wefunder.com/biostate.ai#claim-fact-7
- Headquarter in Houston and palo alto. Subsidiaries in India, China, and Saudi Arabia | citation: https://wefunder.com/biostate.ai#claim-fact-8

FAQ:
- Q: Hi, I'm interested, but quite concerned about your burn rate of $340K per month! Your cash in hand was $2,000,000, as of December 2024. Now that we're at the beginning of February 2025, that would leave $1.66M which covers a little less than 5 months of expenses. By your raise...
  A: We cannot disclose ongoing other fundraising activities, but we have no plans for cuts and have actually expanded the team by roughly 7 people in the past 2 months.
- Q: Your cause is admirable but, you're going to be so outclassed and outcompeted that by the time you are ready to make a profit, you won't have an ounce of investor confidence. Even then the risk reward is, what, at best 50x in 10 years and on the way you will dilute early inves...
  A: Hi Timmy, - With our patented BIRT and PERD technologies, we have an 8x lower cost than ALL competitors, and achieve over 80% gross margins on over 25,000 samples. - Our point about not being profitable for up to 14 years is about net margin/profit, because all of our fundraises and gross profits will be going towards R&D to help people live longer. - Our valuation as of May 2025, assigned by Accel (earliest investors in Facebook and Discord) was $62M. Since that time, we have created sig...
- Q: wow, I was in until I saw the no profit for 14 years mentioned by timmy. I have never seen that time frame in my life and I have over 160 companies in my portfolio and obviously looked at plenty more. that is beyond long term, some of your investors may kick the bucket before ...
  A: Hi John, "Unprofitable for 14 years" is the good outcome, actually, kind of like how Amazon was unprofitable from 1994 to 2003. If the fundraising environment sours, we have the ability to become profitable (and we do have profitable business units). But that will slow our collection of human samples and multiomics datasets, which means that our ultimate goal of treating all diseases becomes farther away.
- Q: Hi. Congrats on your success so far. A few questions, please: 1. You mention pricing for RNA and DNA sequencing tests. Are you monetizing any of your AI tools/services? 2. I see that K-Dense is a spinout of Biostate. Does an investment in Biostate through this campaign also en...
  A: Hi Brian, thanks for your question. 1. Yes, please visit k-dense.ai to try it out! 2. Yes, K-Dense is currently majority owned by Biostate AI, so you get indirect ownership in K-Dense. 3. K-Dense and DNA sequencing are currently available. N-Act requires a prospective clinical trial/study before commercialization; we hope to start the study later this year and complete before end of 2027. 4. The most direct competitor is Tempus AI (nasdaq: tem), an $8B company. They are doing precision medici...
- Q: Thanks for your responses, Dave. One more question, if I may. Your chart shows a revenue projection of $180 million in 2029. Is this figure cumulative? Or do you project to bring in $180 million in revenues in 2029 alone?
  A: Hi Brian, thanks for your question. Multiple Sclerosis (MS) subtyping itself is a $2B / yr market: There are over 1 million Americans affected by this disease, and currently clinicians can only tell when a RRMS has converted to progressive MS 2-5 years after the fact, through MRI scans. A blood test (that we are currently developing) for detecting progressive MS, selling at $2000 / test, and 1 test per year, is $2B / yr. A $180M / yr revenue is estimating a 9% market penetration, which is typ...